Literature DB >> 9852979

The identification of risk factors associated with persistent pain following herpes zoster.

R J Whitley1, S Shukla, R J Crooks.   

Abstract

Demographic and clinical characteristics of patients with herpes zoster at the time of presentation predict the duration and severity of pain on long-term follow-up. Analyses by Cox's proportional hazard models of six databases from controlled trials of antiviral drugs (total subjects = 2367) identified covariates for zoster-associated pain; all tests for significance were two-sided. Age strongly influenced pain outcome: patients > or = 50 years old were significantly more likely to have prolonged zoster-associated pain compared with those < 30 years old. Patients with prodromal symptoms or moderate or severe pain at presentation were also more likely to experience prolonged zoster-associated pain. Neither time to initiating treatment after rash onset nor sex of patient influenced pain outcome. Advancing age, prodromal symptoms, and acute pain severity at presentation predicted those individuals most at risk of prolonged pain and postherpetic neuralgia. When two or more of these factors were present, the risk of persistent pain was increased.

Entities:  

Mesh:

Year:  1998        PMID: 9852979     DOI: 10.1086/514274

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

Review 1.  WITHDRAWN: Topical lidocaine for the treatment of postherpetic neuralgia.

Authors:  Waqas Khaliq; Serena Alam; Naveen Kumar Puri
Journal:  Cochrane Database Syst Rev       Date:  2013-10-28

Review 2.  The placebo response: relationship to outcomes in trials of postherpetic neuralgia.

Authors:  Gordon Irving
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Valaciclovir: a review of its use in the management of herpes zoster.

Authors:  D Ormrod; K Goa
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

Review 4.  Prevention strategies for herpes zoster and post-herpetic neuralgia.

Authors:  Myron J Levin; Anne A Gershon; Robert H Dworkin; Marc Brisson; Lawrence Stanberry
Journal:  J Clin Virol       Date:  2010-05       Impact factor: 3.168

5.  Natural history of pain following herpes zoster.

Authors:  Hans Gustav Thyregod; Michael C Rowbotham; Michelle Peters; Jessica Possehn; Marlene Berro; Karin Lottrup Petersen
Journal:  Pain       Date:  2006-10-27       Impact factor: 6.961

Review 6.  Brivudin (bromovinyl deoxyuridine).

Authors:  Susan J Keam; Therese M Chapman; David P Figgitt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Factors contributing to pain chronicity.

Authors:  Charlie K Wang; Jennifer Myunghae Hah; Ian Carroll
Journal:  Curr Pain Headache Rep       Date:  2009-02

Review 8.  Herpes zoster infection and postherpetic neuralgia.

Authors:  R B Tenser
Journal:  Curr Neurol Neurosci Rep       Date:  2001-11       Impact factor: 6.030

9.  The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

Authors:  Robert W Johnson; Didier Bouhassira; George Kassianos; Alain Leplège; Kenneth E Schmader; Thomas Weinke
Journal:  BMC Med       Date:  2010-06-21       Impact factor: 8.775

Review 10.  A systematic review and meta-analysis of risk factors for postherpetic neuralgia.

Authors:  Harriet J Forbes; Sara L Thomas; Liam Smeeth; Tim Clayton; Ruth Farmer; Krishnan Bhaskaran; Sinéad M Langan
Journal:  Pain       Date:  2016-01       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.